OncLive Welcomes MD Anderson Cancer Center to Strategic Alliance Partnership Program

Article

OncLive today joins with The University of Texas MD Anderson Cancer Center in a partnership to increase awareness of the latest advances in cancer research, treatment and care through OncLive's Strategic Alliance Partnership program.

PLAINSBORO, N.J. (March 10, 2015) — OncLive® today joins with The University of Texas MD Anderson Cancer Center in a partnership to increase awareness of the latest advances in cancer research, treatment and care through OncLive’s Strategic Alliance Partnership program.

In the new partnership, OncLive’s editorial and marketing teams will publicize new developments from MD Anderson, home to the largest cancer clinical trials program in the nation. Located in the Texas Medical Center in Houston, MD Anderson’s mission is to end cancer through outstanding programs that combine patient care, research, education and prevention.

Recognized for its scientific excellence and multidisciplinary approach to researching and treating cancer, MD Anderson is one of 41 National Cancer Institute-designated comprehensive cancer centers in operation today.

Mike J. Hennessy Jr., senior vice president of the Oncology Specialty Group, which includes OncLive, and Specialty Pharmacy at Michael J. Hennessy Associates, Inc., said, “We are honored to partner with MD Anderson Cancer Center to bring important cancer news to everyone committed to fighting the disease. MD Anderson’s research program is considered one of the most productive in the world for cancer, which means they are translating a lot of knowledge from the laboratory into clinical practice — knowledge that could greatly benefit the cancer community.”

Ronald DePinho, M.D., MD Anderson president, said, “Everything we do is about our patients, making sure they have superior care and access to the latest in cancer therapies. The partnership with OncLive will give us another opportunity to connect with even more people who are as passionate as we are about putting an end to cancer.”

MD Anderson Cancer Center joins more than 30 other leading cancer centers, nursing schools and physician groups around the country in partnering with OncLive.

Hennessy added, “The Strategic Alliance Partnership program serves everyone committed to fighting cancer. When we work together and share our knowledge broadly, we are better armed to improve our efforts to overcome this devastating disease.”

About OncLive

OncLive.com is the official website for Intellisphere’s Oncology Specialty Group, which publishes Oncology & Biotech News, OncologyLive, Oncology Nursing News, and Contemporary Oncology. OncLive offers oncology professionals the resources and information they need to provide the best care for their patients. Intellisphere, LLC, a leading provider of healthcare publishing, research and education, is part of the Michael J. Hennessy Associates, Inc. (MJH) family of businesses, based in Plainsboro, N.J. MJH also includes the acclaimed CURE Media Group, which combines science and humanity to make cancer understandable. Its flagship product is CURE magazine, the largest consumer publication in the U.S. focused entirely on cancer, reaching cancer patients, cancer centers and advocacy groups. To learn more, please visit www.OncLive.com.

About MD Anderson

The University of Texas MD Anderson Cancer Center in Houston ranks as one of the world’s most respected centers focused on cancer patient care, research, education and prevention. MD Anderson is one of only 41 comprehensive cancer centers designated by the National Cancer Institute (NCI). For the past 25 years, MD Anderson has ranked as one of the nation’s top two cancer centers in U.S. News & World Report’s annual “Best Hospitals” survey. MD Anderson receives a cancer center support grant from the NCI of the National Institutes of Health (P30 CA016672).

###

Media Contacts

For MD Anderson: Julie A. Penne, 713-792-0662, 281-460-1788 cell, jpenne@mdanderson.org

For OncLive: Becky Taylor, 609-240-6886, becky@btaylorpa.com

Related Videos
Corey Cutler, MD, MPH, and Hana Safah, MD, experts on GvHD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Video 1 - "HR+/HER2- Early-Stage Breast Cancer: Background and Risk Stratification "